Sulfamethoxazole-trimethoprim (SXT) resistance among members of the family Enterobacteriaceae has been recognized for a decade, but resistance in Shigella spp. has been found infrequently (2; R. M. Bannatyne et al., Lancet i: [425] [426] 1980 [letter]; D. E. Taylor et al., Lancet i: 426, 1980 [letter]). SXT is freely available in Brazil and is a common ingredient in many over-the-counter antidiarrheal medications. Perhaps because of the selective pressure caused by increasing, widespread use of this antibiotic combination, doubly resistant coliforms have emerged in recent years (5, 6 ). In the course of studies of inflammatory diarrhea at the Hospital das Clinicas in Fortaleza, Brazil, during January and February 1982, we isolated and performed antibiotic susceptibility tests on four Shigella flexneri strains and found that three of them were highly resistant to SXT. Over the period 1978 to 1980, we isolated 13 Shigella strains from the same area, none of which were resistant to SXT. We also report here the isolation of different large plasmids from each of these SXT-resistant Shigella strains and the transfer of combined resistance with two of these plasmids to recipient strains.
The strains were tested for susceptibility to trimethoprim and sulfamethoxazole by agar dilution on Mueller-Hinton agar with 10% lysed horse blood by using a Steers replicator device (12) . Susceptibility to other antibiotics was determined on Sensititre plates (GIBCO Diagnostics, Lawrence, Mass.).
Transfer of SXT resistance to two nalidixic acid-resistant Escherichia coli K-12 strains, 185Nx (prototroph, Nal) and 711 (lac-28 his-51 trp-30 proC23 phe Nal), was achieved by collecting equal volumes of early-log-phase cultures for matings on nitrocellulose filters (11) . The mating mixture was plated onto Mueller-Hinton agar with 10% lysed horse blood containing nalidixic acid alone (25 ,ug/ml) and onto plates containing sulfamethoxazole (304 ,ug/ml), trimethoprim (16 ,ug/ml), and nalidixic acid (25 pug/ml) (13) . Any transconjugant colonies which resulted from the matings were confirmed as E. coli by the API biochemical identification system (Analytab Products, Plainview, N.Y.). Plasmid DNA was isolated by lysing the bacteria by the procedure of Hansen and Olsen (3), precipitation with polyethylene glycol, and cesium chloride-ethidium bromide ultracentrifugation. Plasmid DNA was separated and characterized by * Corresponding author. agarose gel electrophoresis as described by Meyers et al. (8) .
Three SXT-resistant S. flexneri strains isolated from individuals without any recognized epidemiological link from different areas of town at different times and one SXTresistant Klebsiella pneumoniae strain, designated LP, were mated with SXT-susceptible E. coli K-12 strains to determine whether SXT resistance could be transferred. Two of the three Shigella strains, LP The three S. flexneri strains were resistant to SXT (MIC > 608 and 32 jig/ml respectively), sulfamethoxazole (MIC 2 152 ,ug/ml), trimethoprim (MIC = 500 to 1,000 pug/ml), chloramphenicol, and tetracycline. Two of these strains were resistant to ampicillin (MIC > 128 ,ug/ml) as well. Two SXT-resistant Enterobacteriaceae strains were also isolated from the stools of two patients with SXT-resistant Shigella infections (K. pneumoniae LP and E. coli FG), and one SXT-resistant E. coli strain (RL) was isolated from a patient with diarrhea caused by Campylobacterjejuni. The plasmid DNA from the original three S. flexneri strains, the SXT-resistant fecal E. coli strains FG and RL, and the four transconjugant strains resulting from matings of S. flexneri and K. pneumoniae with E. coli was extracted and then characterized by agarose gel electrophoresis. S.
flexneri FG contained a large plasmid with an approximate molecular weight of 46,000, designated pKF1, in addition to two other bands of lower molecular weight. Only the large plasmid was transferred to E. coli 185Nx, resulting in the formation of a transconjugant strain having the pKF1 plasmid and SXT resistance. The SXT-resistant strain E. coli FG contained two large plasmids of molecular weights different from that of the S. flexneri plasmid pKF1. S. flexneri LP contained a different large plasmid, designated pKF2, with an approximate molecular weight of 30,000, and two fastermigrating bands. Again, only the large plasmid, pKF2, was transferred to both E. coli recipient strains, resulting in the formation of two SXT-resistant transconjugants. Although we did not isolate plasmid DNA from K. pneumoniae LP, SXT resistance was transferred by conjugation from this strain to E. coli 185Nx and was associated with the acquisition by the transconjugant of at least two large plasmids. S.
flexneri MG contained yet another large plasmid, approximately 58 megadaltons in size, which did not transfer to the recipient strains, and there were also several other rapidly migrating bands. Two large plasmids, one of which was similar in size to pKF1, were recovered from the SXTresistant E. coli strain RL isolated from a patient with diarrhea caused by C. jejuni.
Comparison of EcoRI and HindlIl restriction patterns of total plasmid DNA, with two to nine fragments each, showed that there was no overall similarity among the large plasmids recovered from the SXT-resistant S. flexneri strains, but that the fragments corresponded precisely to those of the plasmids from each of the transconjugant strains. The small plasmids were not cleaved by the enzymes we used. Therefore, we could make a direct comparison of the fragments from the large plasmids in the original strains with those in the transconjugants. Thus, SXT resistance is associated with different plasmids in a number of different Enterobacteriaceae strains as well as in the Shigella strains. Furthermore, at least three different plasmids were transferred with SXT resistance to recipient strains in vitro.
Resistance to trimethoprim is becoming widespread, and this threatens the effectiveness of trimethoprim and SXT against infections such as shigellosis and typhoid fever. Particularly widespread amoung Salmonella spp. (perhaps related to the use of trimethoprim in treating animals) (7, 9, 10, 13) , cotransferable SXT resistance is now being recognized among Shigella species from diverse areas (2; Bannatyne et al., letter; Taylor et al., letter) and is documented again here with three different plasmids in various species.
Shigella species frequently cause inflammatory diarrhea characterized by fever, tenesmus, and bloody, mucoid stools, with numerous polymorphonuclear neutrophils (4). Appropriate therapy with an absorbable agent to which the organism is susceptible in vitro results in rapid resolution of symptoms, including diarrhea, fever, and abdominal cramps (1, 14) . The recent emergence of ampicillin-and now SXTresistant strains may preclude effective therapy with these agents.
The transferable SXT resistance of the two S. flexneri and one K. pneumoniae strain was associated with three plasmids of different sizes. Therefore, this SXT resistance does not originate from a single promiscuous plasmid. Furthermore, the association of SXT resistance with more than one plasmid and the different S. flexneri subspecies involved indicate that this is not a single-source outbreak and that the problem may be more widespread than is currently recognized.
SXT resistance was cotransferred with both ampicillin and chloramphenicol resistance from S. flexneri FG to its transconjugant and was associated with the transfer of a single large plasmid. This finding raises still further concern about the continued efficacy of these widely used agents for shigellosis and typhoid fever.
Although we have not documented clinical failure or SXT in these patients; the appearance of Shigella spp. with multiple resistance capable of intergeneric transfer raises concerns about appropriate antimicrobial therapy for shigellosis and other enteric infections in this setting. These data also suggest that multiply resistant pathogens may be increasing in frequency and may pose clinical problems, especially in regions where over-the-counter antibiotics are in common use.
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